Ohri Nitin, Dawson Laura A, Krishnan Sunil, Seong Jinsil, Cheng Jason C, Sarin Shiv K, Kinkhabwala Milan, Ahmed Mansoor M, Vikram Bhadrasain, Coleman C Norman, Guha Chandan
Department of Radiation Oncology (NO, CG) and Montefiore-Einstein Center for Transplantation (MK), Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, NY; Department of Radiation Oncology, Princess Margaret Cancer Centre/University of Toronto, Toronto, Ontario, Canada (LAD); Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX (SK); Department of Radiation Oncology, Yonsei University Hospital, Seoul, North Korea (JS); Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan (JCC); Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India (SKS); Molecular Radiation Therapeutics Branch (MMA) and Clinical Radiation Oncology Branch (BV), Radiation Research Program (CNC), National Cancer Institute, National Institutes of Health, Bethesda, MD.
J Natl Cancer Inst. 2016 Jul 4;108(9). doi: 10.1093/jnci/djw133. Print 2016 Sep.
Hepatocellular carcinoma (HCC) is a leading cause of cancer death worldwide; its incidence is increasing in the United States. Depending on disease extent and underlying liver status, patients may be treated with local, locoregional, and/or systemic therapy. Recent data indicates that radiotherapy (RT) can play a meaningful role in the management of HCC. Here, we review published experiences using RT for HCC, including the use of radiosensitizers and stereotactic RT. We discuss methods for performing preclinical studies of RT for HCC and biomarkers of response. As a part of the HCC Working Group, an informal committee of the National Cancer Institute's Radiation Research Program, we suggest how RT should be implemented in the management of HCC and identify future directions for the study of RT in HCC.
肝细胞癌(HCC)是全球癌症死亡的主要原因;其发病率在美国呈上升趋势。根据疾病范围和潜在肝脏状况,患者可接受局部、局部区域和/或全身治疗。最近的数据表明,放射治疗(RT)在HCC的管理中可以发挥重要作用。在此,我们回顾了使用RT治疗HCC的已发表经验,包括放射增敏剂和立体定向RT的使用。我们讨论了进行HCC RT临床前研究的方法以及反应生物标志物。作为美国国立癌症研究所放射研究计划的一个非正式委员会——HCC工作组的一部分,我们建议RT应如何在HCC管理中实施,并确定HCC RT研究的未来方向。